Fuji Pharma Co. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fuji Pharma Co. Ltd.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.
Alvotech has swiftly advanced in Japan and Canada, as part of its mission to introduce its pipeline of biosimilars across the globe.
Japan's national health insurance scheme will reimburse infertility treatments from April 2022, in a bid to make the treatments more accessible to patients by effectively lowering the cost by 70%. The key strategic aim is to raise a low birth rate and the move is also set to substantially expand the market for such products for both domestic and foreign players.
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.